Integral Health Asset Management LLC acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 225,000 shares of the company's stock, valued at approximately $14,742,000. AstraZeneca accounts for 1.3% of Integral Health Asset Management LLC's investment portfolio, making the stock its 28th biggest position.
Several other institutional investors also recently bought and sold shares of AZN. Tidal Investments LLC increased its holdings in shares of AstraZeneca by 5.8% in the 3rd quarter. Tidal Investments LLC now owns 6,649 shares of the company's stock valued at $518,000 after acquiring an additional 362 shares during the period. Nordea Investment Management AB purchased a new position in shares of AstraZeneca in the 4th quarter valued at $754,000. Diversified Trust Co increased its holdings in shares of AstraZeneca by 5.8% in the 4th quarter. Diversified Trust Co now owns 5,630 shares of the company's stock valued at $369,000 after acquiring an additional 309 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in shares of AstraZeneca by 0.3% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 192,348 shares of the company's stock valued at $12,603,000 after acquiring an additional 607 shares during the period. Finally, Trust Co. of Toledo NA OH increased its holdings in shares of AstraZeneca by 4.6% in the 4th quarter. Trust Co. of Toledo NA OH now owns 7,651 shares of the company's stock valued at $501,000 after acquiring an additional 337 shares during the period. 20.35% of the stock is currently owned by hedge funds and other institutional investors.
AstraZeneca Stock Up 1.3%
AZN stock traded up $0.85 on Friday, hitting $68.81. 3,742,544 shares of the company's stock were exchanged, compared to its average volume of 5,185,747. AstraZeneca PLC has a 12-month low of $61.24 and a 12-month high of $87.68. The firm has a 50 day moving average price of $70.46 and a two-hundred day moving average price of $69.45. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93. The stock has a market cap of $213.40 billion, a P/E ratio of 30.45, a price-to-earnings-growth ratio of 1.42 and a beta of 0.40.
AstraZeneca (NASDAQ:AZN - Get Free Report) last released its earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The firm had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. During the same quarter in the previous year, the company posted $2.06 earnings per share. The company's revenue was up 7.2% compared to the same quarter last year. As a group, equities research analysts expect that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research analysts have recently issued reports on the company. UBS Group upgraded AstraZeneca from a "neutral" rating to a "buy" rating in a report on Thursday, February 13th. BNP Paribas assumed coverage on AstraZeneca in a report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price target on the stock. Finally, Morgan Stanley started coverage on AstraZeneca in a report on Wednesday, February 12th. They issued an "overweight" rating on the stock. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $88.00.
Get Our Latest Report on AstraZeneca
About AstraZeneca
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
See Also
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
